Abstract 3779
Background
HER2-gene mutations are considered to be an important prognostic factor in patients with lung cancer. The aim of our study was to assess the frequency and significance of HER2-gene single nucleotide polymorphisms -1985G>T and P1170AC>G among the patients with small-cell and non-small cell lung cancer and to compare this data to healthy subjects.
Methods
The study was performed among 359 patients (69% males and 31% females; mean age of 59.96 ± 18.24 years) with diagnosis of stage IV small-cell (24.6% of patients) and non-small cell lung cancer (75.4% of patients) compared to 167 healthy subjects (72% males and 28% females; mean age of 69.96 ± 11.74 years). The frequencies of two polymorphisms of the HER-2-gene -1985G>T and P1170A C>G were detected using the quantitative real-time polymerase chain reaction (qRT-PCR) restriction fragment length polymorphism (RFLP) assay. The study was conducted according to the Declaration of Helsinki, the protocol was reviewed and approved by the institutional Ethics committee and all patients provided written informed consent.
Results
We found statistically significant difference in the distribution of genetic mutation variants -1985G>T and P1170A C>G among the patients with lung adenocarcinoma compared to healthy subjects (p < 0.001). The -1985G>T and P1170A C>G allelic variants were not significantly expressed among the patient and control groups in overall subject (p = 0.874).
Conclusions
Our study indicates that the expressions of genetic variants -1985G>T and P1170A C>G is associated with higher risk of development of lung adenocarcinoma. There was no statistical difference among patient and control groups in overall subjects.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1735 - mTOR inhibition in the treatment of resistant breast cancer
Presenter: María Rodriguez
Session: Poster Display session 1
Resources:
Abstract
6068 - Study of Photodynamic therapy in vitro
Presenter: Irene Jiménez Munguía
Session: Poster Display session 1
Resources:
Abstract
3011 - The potential of neratinib plus dasatinib in overcoming and preventing neratinib resistance in HER2-positive breast cancer models
Presenter: Neil Conlon
Session: Poster Display session 1
Resources:
Abstract
2644 - Novel HDACi, MHY446, induces apoptosis via regulation of mitochondria-endoplasmic reticulum interaction in HCT116 human colorectal cancer cells
Presenter: Nam Deuk Kim
Session: Poster Display session 1
Resources:
Abstract
3085 - Dual inhibition of TGF-β and AXL as a novel treatment for colorectal cancer
Presenter: Davide Ciardiello
Session: Poster Display session 1
Resources:
Abstract
1314 - PARP inhibition enhances cisplatin sensitivity in cervical cancer by modulating β-catenin signaling
Presenter: Minakshi Mann
Session: Poster Display session 1
Resources:
Abstract
2417 - Synergistic effect of DSF combined treatment with cisplatin in atypical teratoid/rhabdoid tumors (AT/RT)
Presenter: Seung Ah Choi
Session: Poster Display session 1
Resources:
Abstract
1149 - Reactive oxygen species induced by OSU-A9 inhibit the growth of duodenal cancer and gastric cancer cells through dephosphorylating intranuclear pyruvate kinase muscle isozyme M2
Presenter: Li-Yuan Bai
Session: Poster Display session 1
Resources:
Abstract
1862 - New therapy for intrahepatic cholangiocarcinoma targeted to cancer associated fibroblasts
Presenter: Takahiro Yamanaka
Session: Poster Display session 1
Resources:
Abstract
782 - Macrophage-cancer cell fusion is mediated by Phosphatidylserine-CD36 receptor interaction and induced by ionizing radiation
Presenter: Ivan Shabo
Session: Poster Display session 1
Resources:
Abstract